Clinical Trial

A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in participants with MDD.
Protocol Amendment History 1 change
notable Trial sites expanded: 45 -> 60 locations 2026-07-25
Trial Details
NCT Number NCT07196501
Lead Sponsor Neurocrine Biosciences
Conditions Major Depressive Disorder
Enrollment 550 participants
Start Date 2025-08-18
Primary Completion 2028-07 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-24